• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Henry Schein Announces Completion of Strategic Investment by KKR and Appointment of Dan Daniel to Board of Directors

    5/16/25 4:10:00 PM ET
    $HSIC
    $KKR
    Medical Specialities
    Health Care
    Investment Managers
    Finance
    Get the next $HSIC alert in real time by email

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today announced the successful completion of a $250 million strategic investment by funds affiliated with KKR, a leading global investment firm. Upon the closing of this transaction, KKR has become the holder of approximately 12% of the common shares of Henry Schein.

    In connection with the investment, William K. "Dan" Daniel, Executive Advisor to KKR and former Executive Vice President of Danaher Corporation, has officially joined Henry Schein's Board of Directors as an independent director. He joins Max Lin, Partner at KKR and leader of the firm's Health Care industry team in the Americas, who became a member of Henry Schein's Board of Directors on May 2, 2025.

    Max Lin leads the Health Care industry team within KKR, and since joining in 2005, he has overseen a number of investments in the areas of dental services and other health care providers, medical products and equipment, and health care software and information technology. Dan Daniel has over three decades of global leadership experience in industrial and health care sectors, including 14 years as Executive Vice President at Danaher, where he oversaw multiple segments and played a key role in advancing the company's culture and business system. In connection with each of their appointments, Mr. Lin was appointed to the Nominating and Governance Committee as Vice Chair; Mr. Daniel was appointed to the Compensation Committee; and each of Mr. Lin and Mr. Daniel was appointed to the Strategic Advisory Committee.

    "We are pleased to welcome Max and Dan to the Board as we embark on this exciting next chapter for Henry Schein," said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein. "Their deep experience in health care, operations, and strategic growth will be invaluable as we continue executing on our BOLD+1 strategy and creating long-term value for our stakeholders."

    About Henry Schein, Inc.

    Henry Schein, Inc. (NASDAQ:HSIC) is a solutions company for health care professionals powered by a network of people and technology. With approximately 25,000 Team Schein Members worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.

    Henry Schein operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products and Henry Schein corporate brand products in our distribution centers.

    A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 33 countries and territories. The Company's sales reached $12.7 billion in 2024, and have grown at a compound annual rate of approximately 11.2 percent since Henry Schein became a public company in 1995.

    For more information, visit Henry Schein at www.henryschein.com, Facebook.com/HenrySchein, Instagram.com/HenrySchein, LinkedIn.com/Company/HenrySchein, and @HenrySchein on X.

    About KKR

    KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR's insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR's investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE:KKR), please visit KKR's website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group's website at www.globalatlantic.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250516439220/en/

    Investors

    Ronald N. South

    Senior Vice President and Chief Financial Officer

    [email protected]

    (631) 843-5500



    Graham Stanley

    Vice President, Investor Relations and Strategic Financial Project Officer

    [email protected]

    (631) 843-5500



    Media

    Henry Schein

    Tim Vassilakos

    Executive Director, Global Corporate Communications

    [email protected]

    (516) 510-0926



    KKR

    Liidia Liuksila

    [email protected]

    Get the next $HSIC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HSIC
    $KKR

    CompanyDatePrice TargetRatingAnalyst
    KKR & Co. Inc.
    $KKR
    1/14/2026$131.00Buy → Hold
    TD Cowen
    KKR & Co. Inc.
    $KKR
    12/11/2025$176.00Buy
    UBS
    Henry Schein Inc.
    $HSIC
    12/9/2025$86.00Overweight
    Barclays
    Henry Schein Inc.
    $HSIC
    8/26/2025$83.00In-line → Outperform
    Evercore ISI
    Henry Schein Inc.
    $HSIC
    7/25/2025$75.00Buy → Hold
    Stifel
    KKR & Co. Inc.
    $KKR
    7/14/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    Henry Schein Inc.
    $HSIC
    7/14/2025$72.00Outperform → Neutral
    Robert W. Baird
    KKR & Co. Inc.
    $KKR
    7/9/2025$142.00Buy → Hold
    HSBC Securities
    More analyst ratings

    $HSIC
    $KKR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Daniel William K bought $670,800 worth of shares (10,000 units at $67.08) (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    8/11/25 4:26:33 PM ET
    $HSIC
    Medical Specialities
    Health Care

    Director Barakett Timothy R bought $4,127,319 worth of shares (35,000 units at $117.92) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Issuer)

    5/27/25 8:01:38 PM ET
    $KKR
    Investment Managers
    Finance

    Director Scully Robert W bought $1,503,733 worth of shares (13,250 units at $113.49) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Issuer)

    5/8/25 7:01:53 PM ET
    $KKR
    Investment Managers
    Finance

    $HSIC
    $KKR
    SEC Filings

    View All

    KKR & Co. Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

    8-K - KKR & Co. Inc. (0001404912) (Filer)

    1/16/26 4:30:45 PM ET
    $KKR
    Investment Managers
    Finance

    SEC Form 8-K filed by Henry Schein Inc.

    8-K - HENRY SCHEIN INC (0001000228) (Filer)

    1/12/26 7:00:12 AM ET
    $HSIC
    Medical Specialities
    Health Care

    KKR & Co. Inc. filed SEC Form 8-K: Leadership Update

    8-K - KKR & Co. Inc. (0001404912) (Filer)

    1/9/26 4:30:43 PM ET
    $KKR
    Investment Managers
    Finance

    $HSIC
    $KKR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    KKR Increases Ownership Stake in Altavair

    KKR, a leading global investment firm, and Altavair, a leader in commercial aviation leasing and financing, today announced a definitive agreement under which KKR will increase its ownership stake in Altavair and its sister company, AV AirFinance. KKR will fund the investment from its balance sheet. The new investment deepens the long-term strategic partnership between KKR and Altavair, which invests across the global leased aircraft market. KKR-managed funds have committed more than $5 billion to aircraft leasing and lending transactions since the strategic partnership launched in 2018. "We are pleased to build on our long-standing relationship with Altavair and reinforce our commitmen

    1/19/26 3:00:00 AM ET
    $KKR
    Investment Managers
    Finance

    Henry Schein Enters Exclusive Distribution Agreement for CytoChip's CLIA-Waived Hematology Analyzer

    Partnership Expands Access to FDA-Cleared CitoCBC® System Across the U.S. Henry Schein, Inc. (NASDAQ:HSIC) has entered into a new exclusive distribution agreement with CytoChip Inc. for its flagship product, the CitoCBC® system, a U.S. Food and Drug Administration (FDA) 510(k)-cleared device. Available now to Henry Schein customers in the United States, the CitoCBC system is the first cartridge-based Complete Blood Count (CBC) system to receive a CLIA Waiver, helping expand access to accurate, lab-quality testing at the point of care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115495488/en/CLIA Waived CitoCBC System Des

    1/15/26 10:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    KKR Completes US$2.5 Billion Asia Private Credit Fundraise

    KKR, a leading global investment firm, today announced the completion of a US$2.5 billion fundraise focused on committing capital to privately originated performing credit investments in Asia Pacific. The fundraise includes US$1.8 billion in KKR Asia Credit Opportunities Fund II ("ACOF II" or the "Fund") and US$700 million raised from separately managed accounts focused on the same types of investment opportunities. At close, the Fund is the largest pan-regional performing private credit fund in Asia Pacific. This closely follows KKR's inaugural Asia Pacific-dedicated private credit fund, KKR Asia Credit Opportunities Fund, which closed at US$1.1 billion in 2022 as the largest inaugural p

    1/14/26 8:04:00 PM ET
    $KKR
    Investment Managers
    Finance

    $HSIC
    $KKR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    KKR downgraded by TD Cowen with a new price target

    TD Cowen downgraded KKR from Buy to Hold and set a new price target of $131.00

    1/14/26 8:26:34 AM ET
    $KKR
    Investment Managers
    Finance

    UBS resumed coverage on KKR with a new price target

    UBS resumed coverage of KKR with a rating of Buy and set a new price target of $176.00

    12/11/25 9:10:54 AM ET
    $KKR
    Investment Managers
    Finance

    Barclays initiated coverage on Henry Schein with a new price target

    Barclays initiated coverage of Henry Schein with a rating of Overweight and set a new price target of $86.00

    12/9/25 8:50:15 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    $KKR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Kkr Alternative Assets Llc acquired $3,349,422 worth of Class I Common Stock (142,832 units at $23.45) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Reporting)

    1/5/26 4:05:41 PM ET
    $KKR
    Investment Managers
    Finance

    Director Niel Xavier Bruno was granted 1,605 shares, increasing direct ownership by 5% to 31,878 units (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Issuer)

    12/12/25 7:00:54 PM ET
    $KKR
    Investment Managers
    Finance

    Director Russo Patricia F was granted 1,605 shares, increasing direct ownership by 2% to 88,464 units (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Issuer)

    12/12/25 7:00:57 PM ET
    $KKR
    Investment Managers
    Finance

    $HSIC
    $KKR
    Leadership Updates

    Live Leadership Updates

    View All

    Henry Schein Enters Exclusive Distribution Agreement for CytoChip's CLIA-Waived Hematology Analyzer

    Partnership Expands Access to FDA-Cleared CitoCBC® System Across the U.S. Henry Schein, Inc. (NASDAQ:HSIC) has entered into a new exclusive distribution agreement with CytoChip Inc. for its flagship product, the CitoCBC® system, a U.S. Food and Drug Administration (FDA) 510(k)-cleared device. Available now to Henry Schein customers in the United States, the CitoCBC system is the first cartridge-based Complete Blood Count (CBC) system to receive a CLIA Waiver, helping expand access to accurate, lab-quality testing at the point of care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115495488/en/CLIA Waived CitoCBC System Des

    1/15/26 10:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Names Frederick M. Lowery as Chief Executive Officer

    Industry veteran brings more than 20 years of healthcare distribution experience and operational excellence Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical professionals, today announced the appointment of Frederick M. Lowery as its new Chief Executive Officer ("CEO"), effective March 2, 2026, at which time he will join the Board of Directors. Mr. Lowery succeeds Stanley M. Bergman, who will step down as CEO after 35 years and continue to serve as Chairman of the Board to ensure a smooth and effective leadership transition. This press release features multimedia. View the full release here: https://www.businesswire

    1/12/26 7:00:00 AM ET
    $HSIC
    $TMO
    Medical Specialities
    Health Care
    Industrial Machinery/Components
    Industrials

    Peak Re Welcomes KKR and Quadrantis Capital as Minority Investors

    Peak Reinsurance Company Limited ("Peak Re" or the "Company") and KKR, a leading global investment firm, today announced that funds managed by KKR and Quadrantis Capital have entered into definitive agreements to acquire minority stakes in Peak Re via Peak Reinsurance Holdings Limited. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020924186/en/ Upon completion, KKR and Quadrantis Capital are expected to hold approximately 11.27% and approximately 1.80% of Peak Re's issued share capital, respectively, with the remaining approximately 86.71% continuing to be held by the majority shareholder, Fosun International Limited. Pruden

    10/20/25 9:05:00 PM ET
    $KKR
    Investment Managers
    Finance

    $HSIC
    $KKR
    Financials

    Live finance-specific insights

    View All

    KKR & Co. Inc. to Announce Fourth Quarter 2025 Results

    KKR & Co. Inc. (NYSE:KKR) announced today that it plans to release its financial results for the fourth quarter 2025 on Thursday, February 5, 2026, before the opening of trading on the New York Stock Exchange. A conference call to discuss KKR's financial results will be held on Thursday, February 5, 2026 at 9:00 a.m. ET. The conference call may be accessed by dialing (877) 407-0312 (U.S. callers) or +1 (201) 389-0899 (non-U.S. callers); a pass code is not required. Additionally, the conference call will be broadcast live over the Internet and may be accessed through the Investor Center section of KKR's website at https://ir.kkr.com/events-presentations/. A replay of the live broadcast wil

    1/6/26 4:15:00 PM ET
    $KKR
    Investment Managers
    Finance

    KKR Acquires Cheongna Logistics Center

    Transaction marks the largest single asset logistics transaction in South Korea KKR, a leading global investment firm, and its affiliated Korean asset manager, Kreate Asset Management ("Kreate"), today announced the completion of the acquisition of Cheongna Logistics Center, a high-quality logistics facility located in Incheon, invested by funds managed by KKR, through a fund managed by Kreate in Korea. This represents the largest single asset logistics transaction in Korea to date. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251229774474/en/ Completed in 2022, Cheongna Logistics Center is a large-scale, modern 4.6-million

    12/29/25 9:09:00 PM ET
    $KKR
    Investment Managers
    Finance

    KKR Announces Intra-Quarter Monetization Activity Update for the Fourth Quarter

    KKR today announced income from monetization activity in excess of $525 million with respect to the period from October 1, 2025 through December 19, 2025 based on information available as of today. The quarter-to-date monetization activity is made up of approximately 95% realized performance income and approximately 5% realized investment income. Approximately 45% of realized performance income is driven by revenues from our strategic hedge fund partnerships that correspond to a 10-20% compensation rate. The monetization figures above exclude the impact of the previously disclosed Asian Fund II obligation. The quarter-to-date monetization activity is driven by a combination of public seco

    12/19/25 4:15:00 PM ET
    $KKR
    Investment Managers
    Finance

    $HSIC
    $KKR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Henry Schein Inc.

    SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

    11/13/24 3:30:01 PM ET
    $HSIC
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by KKR & Co. Inc.

    SC 13G/A - KKR & Co. Inc. (0001404912) (Subject)

    11/12/24 3:50:17 PM ET
    $KKR
    Investment Managers
    Finance

    SEC Form SC 13G filed by Henry Schein Inc.

    SC 13G - HENRY SCHEIN INC (0001000228) (Subject)

    11/12/24 9:32:27 AM ET
    $HSIC
    Medical Specialities
    Health Care